Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Friday, 05 / 14 / 2021



New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis

Sanja Stojsavljevic-Shapeski1, Marko Duvnjak*,2,3, Lucija Virovic-Jukic1,4, Davor Hrabar1,4 and Lea Smircic Duvnjak4,5

1  Department of Gastroenterology and Hepatology, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia
2  Polyclinic Duvnjak, Zagreb, Croatia
3  University of Applied Health Science, Zagreb, Croatia
4  School of Medicine, University of Zagreb, Zagreb, Croatia
5  Vuk Vrhovac University Clinic-UH Merkur, Zagreb, Croatia
*Correspondence to: Marko Duvnjak, Polyclinic Duvnjak, Kukuljeviceva 2, Zagreb 10000, Croatia. Tel: +38-5989838930, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2021;9(1):51-59 DOI: 10.14218/JCTH.2020.00057
Received: June 20, 2020 Accepted: October 21, 2020 Published online: November 27, 2020


Patients with nonalcoholic steatohepatitis (NASH) are at higher risk of progression to advanced stages of fibrosis, cirrhosis, hepatocellular carcinoma and other end-stage liver disease complications. When addressing treatment of NASH, we have limited approved options, and the mainstay of therapy is lifestyle intervention. Extensive research and revelation in the field of pathogenesis of NASH has offered new possibilities of treatment and emerging new drugs that are being tested currently in numerous preclinical and clinical trials. These drugs target almost all steps in the pathogenesis of NASH to improve insulin sensitivity, glucose and lipid metabolism, to inhibit de novo lipogenesis and delivery of lipids to the liver, and to influence apoptosis, inflammation and fibrogenesis. Although NASH is a multifactorial disease, in the future we could identify the predominating pathological mechanism and, by choosing the most appropriate specific medication, tailor the treatment for every patient individually.


Fatty liver, Steatohepatitis, Nonalcoholic fatty liver disease, Treatment

Journal of Clinical and Translational Hepatology 2021 vol. 9, 51-59  [ Html  ] [ PDF Full-text ]

© The Author(s) 2021. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.


You are here: Home